AstraZeneca has opened a new global strategic R&D facility in Massachusetts, US, as part of an investment of more than $1bn in the state.

The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, as pharma explores its role on treating ophthalmic conditions.

Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours.

Established CDMO Piramal Pharma Solutions is exhibiting at the forthcoming CPHI Milan 2026. The event will showcase the latest innovations in drug development, manufacturing, supply chains, and ...

Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.

Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines.

Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their pipeline horizon – the companies have agreed to expand ...

Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Key themes of CPHI 2026, the GLP-1 manufacturing shift, cold chain logistics, and more.